Using nasal anti-CD3 to reduce inflammation after traumatic brain injury
Targeting CNS Neuroinflammation in Traumatic Brain Injury by Nasal Anti-CD3
This study is testing a new nasal treatment for people with traumatic brain injury that uses special antibodies to help calm down inflammation in the brain, with the hope of improving recovery.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11064802 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating traumatic brain injury (TBI) by using nasal anti-CD3 monoclonal antibodies to reduce neuroinflammation. The study focuses on how this treatment can modulate the immune response, particularly the activation of microglia, which are immune cells in the brain that contribute to inflammation after injury. By administering the treatment nasally, the researchers aim to induce regulatory T cells that can migrate to the brain and help control inflammation. This approach is based on previous findings in animal models and seeks to explore its effectiveness in humans.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently sustained a traumatic brain injury and are experiencing neuroinflammation.
Not a fit: Patients with chronic traumatic brain injury or those who do not have an active inflammatory response may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic option that significantly improves recovery and reduces long-term cognitive issues for patients with traumatic brain injury.
How similar studies have performed: While the use of nasal anti-CD3 in the context of traumatic brain injury is novel, similar approaches have shown promise in other conditions like multiple sclerosis.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Izzy, Saef — Brigham and Women's Hospital
- Study coordinator: Izzy, Saef
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.